TUSTIN, CA--(Marketwire - June 02, 2010) -
| Highlighted Links |
|
|
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and viral infections, today announced it will present at Needham & Company’s Ninth Annual Healthcare Conference on Wednesday, June 9, 2010 at 11:20 am EDT. The conference will be held at the New York Palace Hotel in New York City.
A live webcast of the company’s presentation will be available in the Investors section of Peregrine’s website at http://www.peregrineinc.com. A replay will be available on the Peregrine website and will be archived for 30 days.
For more information about this conference, please visit:
http://www.needhamco.com/Default/InstitutionalSalesAndTrading/Conferences.aspx
About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company with a portfolio of innovative monoclonal antibodies in development for the treatment of cancer and serious viral infections. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara®. Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.
